Bio News

MediPost’s Cartistem succeeds in Japanese phase 3 trial, achieving significance for primary and secondary endpoints

MediPost’s knee osteoarthritis treatment Cartistem achieved statistical significance for both the primary and secondary endpoints in a Japanese phase 3 clinical trial, announcing successful results in May 2026. The trial enrolled patients with knee osteoarthritis classified as K&

2026-05-15

Samsung Biologics Acquires GSK’s U.S. Subsidiary for 510 Billion Won, Increasing Production Capacity by 845,000 L

Samsung Biologics invested approximately 510 billion won to acquire GSK’s U.S. subsidiary, increasing its total production capacity to 845,000 L. Through the acquisition, the company secured its first local production site in Maryland, with a capacity of 60,000 L, and completed G

2026-05-15

LigaChem Biosciences Secures 9.4 Trillion Won in Cumulative ADC Contract Milestones, Reports 32.8 Billion Won in First-Quarter Licensing Revenue

LigaChem Biosciences generated 32.8 billion won in revenue from licensing deals alone in the first quarter of this year, securing 9.4 trillion won in cumulative contract milestones. The results reflect development progress across multiple ADC pipelines, including the TROP2 ADC LC

2026-05-15

Samjin Pharmaceutical Introduces Alzheimer Disease Drug Candidate AR1001 in Deal Worth 100 Billion Won

Samjin Pharmaceutical is conducting a global phase 3 trial of AriBio’s oral Alzheimer disease treatment AR1001, which it introduced under a deal worth a total of 100 billion won. The agreement gives Samjin Pharmaceutical exclusive rights to produce and sell AR1001 in South Korea.

2026-05-15

Aprogen halts Phase 3 trial of Herceptin biosimilar, pursues ‘Phase 3 exemption’ approval

Aprogen has halted the Phase 3 trial of its Herceptin biosimilar AP063 and will shift to a “Phase 3 exemption” approval strategy beginning in 2026. The decision follows European Medicines Agency (EMA) guidance allowing marketing applications based solely on Phase 1 data. The stra

2026-05-15

Peptron Ends 4 Billion Won GLP-1 Contract With Yuhan Corp., Pursues Global Licensing Directly

Peptron has ended its 4 billion won domestic contract with Yuhan Corp. for a diabetes treatment (GLP-1) after 13 years. The company has thereby recovered all rights, including the phase 2 clinical trial data, and will pursue global out-licensing directly. It is also preparing a g

2026-05-15

Theragen Bio Develops mRNA Vaccine Aiming to Cut Cancer Recurrence by 50%, Secures Two LNP Candidates

Theragen Bio has begun developing an mRNA vaccine aimed at reducing cancer recurrence by 50%. Selected as a government ARPA-H project, the research has secured two final lipid nanoparticle (LNP) drug-delivery candidates and registered two patents on mRNA structures. The company a

2026-05-15

Deepnoid increases R&D investment by 262% of revenue, focusing on development of large-scale generative AI

Deepnoid is focusing on developing large-scale AI technologies, investing 935 million won in research and development during the first quarter, equivalent to 262% of its revenue of 357 million won. The company is carrying out government-funded projects, including medical-specific

2026-05-15

OliPass Transfers Drug Candidate Targeting 90% of ALS Cases to Subsidiary

OliPass has transferred the patent for a drug candidate targeting more than 90% of patients with amyotrophic lateral sclerosis (ALS), STMN2, to Exona, its wholly owned subsidiary. The candidate works by normalizing STMN2 protein expression and is currently in the preclinical stag

2026-05-15

Cellid’s Next-Generation COVID-19 Vaccine ‘LP.8.1’ Clinical Trial Application Rejected

Cellid’s domestic Phase 2 clinical trial application for its next-generation COVID-19 vaccine ‘LP.8.1’ was rejected due to “insufficient data.” The vaccine targets a variant that the WHO recommended as a circulating strain for 2025-2026, and the application was submitted on Feb.

2026-05-15